# GLP-1 Medications Transform Weight Loss Market as Safety Concerns Emerge

# SEO-Friendly Podcast Episode Description

## Navigating Ozempic: FDA Approves First GLP-1 Weight Loss Pill - Foundayo vs. Wegovy Battle Begins

Discover the latest breakthrough in weight loss medications as the FDA approves **Eli Lilly's Foundayo** (orforglipron), the first oral GLP-1 pill for obesity treatment. This episode of Navigating Ozempic covers the groundbreaking approval that's reshaping the $100 billion metabolic health market.

**What You'll Learn:**
- **Foundayo approval details**: The first daily pill alternative to weekly Ozempic and Wegovy injections
- **Clinical results**: 12.4% average weight loss over 72 weeks
- **Affordable pricing**: As low as $25/month with insurance, $149 self-pay
- **Market competition**: Eli Lilly vs. Novo Nordisk in the GLP-1 obesity drug wars
- **Important safety updates**: Latest FDA warnings on gastroparesis, kidney injury, and pancreatitis
- **Lawsuit information**: 2,914 active cases against GLP-1 manufacturers
- **Good news**: FDA removes suicidal ideation warnings after comprehensive review
- **Women's health concerns**: Muscle loss risks and metabolic implications
- **Cardiovascular benefits**: New Health Canada approval for heart disease protection

**Keywords**: Ozempic, Foundayo, orforglipron, Wegovy, GLP-1 medications, weight loss pills, semaglutide, obesity treatment, metabolic health, FDA approval, Eli Lilly, Novo Nordisk

Perfect for anyone considering GLP-1 medications, healthcare professionals, or those tracking pharmaceutical industry developments.

*A Quiet Please Production*

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI